A nonclinical safety and pharmacokinetic evaluation of N6022: A first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma

► Two weeks of daily N6022 via IV administration was well tolerated. ► High doses of N6022 caused possible liver toxicity related to redox status. ► Inhibiting GSNOR does not cause systemic toxicity.